Allergan and Perrigo said Monday that the initial shipments of the new store-brand product, which began in December, mark a first-to-market achievement for the companies.
“This first-to-market launch illustrates the power of combining Allergan’s world-class generics R&D capabilities with Perrigo’s leadership in OTC and store brand products,” stated Robert Stewart, executive vice president and president of generics and global operations at Allergan. “By leveraging our combined expertise, we are making a high-quality, more affordable store-brand alternative to the Mucinex D extended-release product available for the first time to patients in the U.S., and delivering on our shared commitment to providing patients around the globe with increased access to affordable, high-quality medicines.”
The products are packaged and marketed as store brands or retailer “own label” brands and provide consumers a value alternative to Reckitt Benckisers’ Mucinex D extended-release product, an expectorant and nasal decongestant indicated to relieve chest congestion and sinus congestion and pressure, according to Allergan and Perrigo. The companies reported that Mucinex D had sales of about $46 million through food, drug and mass merchants during the last 12 months.
“This launch is a significant milestone in the partnership between Perrigo and Allergan, and we are pleased to be the first company to bring this complex product to the market,” Perrigo chairman, president and CEO Joseph Papa commented. “This is another excellent example of Perrigo’s commitment to making quality health care more affordable for consumers around the globe.”
Perrigo also is launched the balance of the range of five additional Mucinex-comparable products to the U.S. store-brand market over the first half of calendar year 2016, Papa added. “A full range of Mucinex-comparable products for the store-brand market has been eagerly anticipated by retailers and consumers to provide them high-quality, value alternatives to the national brand,” he stated.
Separately, Perrigo announced the temporary suspension of sales of its guaifenesin 600-mg extended- release product pending the resolution of challenges related to an excipient used in the production of the product.